The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Concordance between PD-L1 assays for metastatic renal cell carcinoma (mRCC) and metastatic urothelial carcinoma (mUC).
 
Jason Zhu
Consulting or Advisory Role - Bayer
Travel, Accommodations, Expenses - UroToday
 
Matthew Labriola
No Relationships to Disclose
 
Sachica Cheris
No Relationships to Disclose
 
Xin Liu
No Relationships to Disclose
 
Kathryn Perkinson
No Relationships to Disclose
 
Zuowei Su
No Relationships to Disclose
 
Shannon McCall
No Relationships to Disclose
 
Jiaoti Huang
Stock and Other Ownership Interests - KingMed Diagnostics; More Health; Optra SCAN
Honoraria - Abbvie
Consulting or Advisory Role - Gem Flower Healthcare
Research Funding - Fortis; Zenith Epigenetics
Travel, Accommodations, Expenses - Gem Flower Healthcare (I)
 
Rajan Gupta
Honoraria - Bayer Schering Pharma; InvivoCorp
Consulting or Advisory Role - Bard Medical; Bayer Schering Pharma; InvivoCorp
Speakers' Bureau - Bayer Schering Pharma
 
Andrew J. Armstrong
Honoraria - Dendreon; Janssen Oncology; Sanofi
Consulting or Advisory Role - Astellas Scientific and Medical Affairs Inc; Bayer; Dendreon; Janssen Biotech; Medivation; Novartis; Pfizer; Sanofi
Speakers' Bureau - Bayer; Dendreon; Sanofi
Research Funding - Active Biotech (Inst); Astellas Pharma (Inst); Bayer (Inst); Bristol-Myers Squibb (Inst); Dendreon (Inst); Gilead Sciences (Inst); Janssen Oncology (Inst); Medivation (Inst); Novartis (Inst); Pfizer (Inst); Roche/Genentech (Inst); Sanofi (Inst)
Patents, Royalties, Other Intellectual Property - Circulating tumor cell novel capture technology (Inst)
Travel, Accommodations, Expenses - Astellas Scientific and Medical Affairs Inc; Bayer; Dendreon; Janssen Biotech
 
Daniel J. George
Honoraria - Bayer; Exelixis; Sanofi
Consulting or Advisory Role - Astellas Pharma; Bayer; Bristol-Myers Squibb; Exelixis; Genentech; Innocrin Pharma; Janssen; Merck Sharp & Dohme; Myovant Sciences; Pfizer; Sanofi
Speakers' Bureau - Bayer; Exelixis; Sanofi
Research Funding - Acerta Pharma (Inst); Astellas Pharma (Inst); Bayer (Inst); Bristol-Myers Squibb (Inst); Dendreon (Inst); Exelixis (Inst); Innocrin Pharma (Inst); Janssen Oncology (Inst); Novartis (Inst); Pfizer (Inst)
Travel, Accommodations, Expenses - Bayer; Exelixis; Merck; Pfizer; Sanofi
 
Tian Zhang
Leadership - Capio BioSciences (I)
Stock and Other Ownership Interests - Capio Biosciences (I)
Honoraria - Exelixis; Genentech/Roche
Consulting or Advisory Role - AstraZeneca; Bayer; Bristol-Myers Squibb; Exelixis; Foundation Medicine; Genentech/Roche; Janssen; Pfizer; Pharmacyclics; Sanofi
Speakers' Bureau - Exelixis; Genentech/Roche; Genomic Health; Genzyme
Research Funding - Acerta Pharma (Inst); Janssen (Inst); Merck (Inst); Merrimack (Inst); Novartis (Inst); OmniSeq (Inst); Personal Genome Diagnostics (Inst); Pfizer (Inst); Regeneron (Inst); Stem CentRx (Inst)
Patents, Royalties, Other Intellectual Property - Circulating tumor cell novel capture by c-MET technology (Inst); Prochelators as Targeted Prodrugs for Prostate Cancer (Inst)
Travel, Accommodations, Expenses - Acerta Pharma